Memantina Tecnigen (Memantine Hydrochloride)

Memantine is a non‑competitive NMDA‑receptor antagonist. It binds within the receptor‑associated ion channel, preventing excessive calcium influx that results from prolonged glutamate stimulation. By reducing excitotoxic neuronal damage, it helps maintain synaptic integrity in Alzheimer’s disease.

The dosage regimen for Memantina Tecnigen is determined by the prescribing clinician based on the patient’s clinical condition, renal function and tolerability. The prescriber will select the appropriate strength and titration schedule according to approved labeling and individual needs.

The safety of memantine during pregnancy and lactation has not been firmly established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified health professional.

To request supply, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for moderate to severe Alzheimer’s disease is donepezil, an acetylcholinesterase inhibitor. Memantine targets the glutamatergic system, whereas donepezil enhances cholinergic transmission. Clinical practice often combines both agents to address different pathophysiological pathways, but the choice depends on patient response, tolerability and physician judgment.

Memantina Tecnigen should be stored at ambient temperature, preferably below 25 °C, in the original container to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

The medication is taken orally, usually once or twice daily as directed by the prescriber. Tablets should be swallowed whole with water and may be taken with or without food. Patients should follow the dosing schedule provided on the prescription label.

Although uncommon, serious adverse events can include severe skin reactions such as Stevens‑Johnson syndrome, seizures, and marked hypertension. Patients should seek immediate medical attention if they develop rash, blistering, unexplained convulsions, or a sudden increase in blood pressure.

Memantina Tecnogen is contraindicated in patients with known hypersensitivity to memantine or any of its excipients. Caution is also advised for individuals with severe renal impairment, uncontrolled epilepsy, or those receiving other NMDA‑receptor antagonists, as the risk of adverse effects may be heightened.